Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 3, 2012, Pages 1464-1468

  Sutton, Jon M ^a   Clark, David E ^a   Dunsdon, Stephen J ^a   Fenton, Garry ^a   Fillmore, Amanda ^a   Harris, Neil V ^a   Higgs, Chris ^a   Hurley, Chris A ^a   Krintel, Sussie L ^a   MacKenzie, Robert E ^a   Duttaroy, Alokesh ^b   Gangl, Eric ^b   Maniara, Wiesia ^b   Sedrani, Richard ^c   Namoto, Kenji ^c   Ostermann, Nils ^c   Gerhartz, Bernd ^c   Sirockin, Finton ^c   Trappe, Jörg ^c   Hassiepen, Ulrich ^c   Baeschlin, Daniel K ^c   more..

^a Argenta Discovery Ltd   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

DPP 4 inhibitor; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EX VIVO STUDY; IC 50; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ANIMALS; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME ACTIVATION; HETEROCYCLIC COMPOUNDS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 84856210285     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.054     Document Type: Article

References (25)

1. J.A. Pospisilik, S.G. Stafford, H.-U. Demuth, R. Brownsey, H. Parkhouse, D.T. Finegood, C.H.S. McIntosh, and R.A. Pederson Diabetes 51 2002 943
2. D.J. Drucker Endocrinology 144 2003 5145
3. K.G. Murphy, W.S. Dhillo, and S.R. Bloom Endocrine Rev. 27 2006 719
4. R. Mentlein, B. Gallwitz, and W.E. Schmidt Eur. J. Biochem. 214 1993 829
5. T.J. Kieffer, C.H.S. McIntosh, and R.A. Pederson Endocrinology 136 1995 3585
6. B. Thorens Diabetes Metab. 21 1995 311
7. J.J. Meier, M.A. Nauck, W.E. Schmidt, and B. Gallwitz Regul. Pept. 101 2002 1
8. http://www.fiercebiotech.com/press-releases/galvus-new-treatment- patients-type-2-diabetes-receives-european-approval.
9. T. Biftu, G. Scapin, S. Singha, D. Fenga, J.W. Becker, G. Eiermann, H. Hea, K. Lyonsa, S. Patela, A. Petrovb, R. Sinha-Royc, B. Zhang, J. Wuc, X. Zhang, G.A. Dossd, N.A. Thornberry, and A.E. Weber Bioorg. Med. Chem. Lett. 17 2007 3384
10. M. Eckhardt, E. Langkopf, M. Todayyon, L. Thomas, H. Nar, W. Pfrengle, B. Guth, R. Lotz, P. Sieger, H. Fuchs, and F. Himmelsbach J. Med. Chem. 50 2007 6450
11. C.F. Deacon, and J.J. Holst Expert Opin. Investig. Drugs 19 1 2010 133
12. E. Matthias, N. Hauel, F. Himmelsbach, E. Langkopf, H. Nar, M. Todayyon, L. Thomas, B. Guth, and R. Lotz Bioorg. Med. Chem. Lett. 18 2008 3158
13. H. Havale, and M. Pal Bioorg. Med. Chem. 17 2009 1783
14. Pyrrolopyrimidinones with deviating structure have been reported as DPP-4 inhibitors in Nakahira, H., Kimura, H., Hochigai, H. WO2006/068163; Y. Nishio, H. Kimura, S. Tosaki, E. Sugaru, M. Sakai, M. Horiguchi, Y. Masui, M. Ono, T. Nakagawa, and H. Nakahira Bioorg. Med. Chem. Lett. 20 2010 7246
15. M.R. Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, and K.A. Dugi Diabetes Obes. Metab. 13 2011 65
16. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.
17. Kataoka, K., Kosugi, T., Ishii, T., Takeuchi, T., Tsutsumi, T., Nakano, A., Unoki, G., Yamamoto, M., Sakai, Y. WO2003/070729.
18. Compounds were tested for their inhibitory potency against human DPP-4. Human DPP-4 (amino acids 39-766) with a C-terminal step-tag was expressed using the baculovirus system and purified to >80%, and stored in a 25 mM Tris buffer, pH 9, containing 300 mM NaCl at -80 °C. The substrate was kept at 5 mM stock solution in DMSO at -20 °C and the assay buffer for the DPP-4 reaction was 25 nM Tris/HCl, pH 7.5, containing 140 mM NaCl, 10 mM KCl and 0.05% (w/v) CHAPS.
19. This observed boost in affinity moving from piperazine to aminopiperidine has been rationalised in terms of an additional hydrogen bonding ability and lower energy conformation: M. Engel, T. Hoffmann, S. Manhart, U. Heiser, S. Chambre, R. Huber, H.-U. Demuth, and W. Bode J. Mol. Biol. 356 2006 768
20. Linagliptin was prepared according to Himmelsbach, F., Langkopf, E., Eckhardt, M., Mark, M., Maier, R., Todayyon, M. WO2004/018468.
21. Milton, J., Wren, S., Wang, S., Folkes, A., Chuckowree, I., Hancox, T; Miller, W., Sohal, S. WO2004065389.
22. G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.-C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, K.A. Lyons, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry Diabetes 54 2005 2988
23. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark J. Pharmacol. Exp. Ther. 325 2008 175
24. Himmelsbach, F., Mark, M., Tadayyon, M., Thomas, L. WO2009/024542.
25. Baeschlin, D. K., Clark, D. E., Dunsdon, S. J., Fenton, G., Fillmore, A., Harris, N. V., Higgs, C., Hurley, C. A., Krintel, S. L., MacKenzie, R. E., Ostermann, N., Sirockin, F., Sutton, J. M. WO2007/071738.